gsk159797
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00354666)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=CNc1cc([C@@H](O)CNCCc2ccc(NC[C@H](O)c3ccccc3)cc2)ccc1O- Mol. weight
- 435.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1940832 ↗
Also known as
- gsk159797
- gsk159797
- gsk159797
- gsk159797
- milveterol
- milveterol
- td-3327
- td-3327
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00358488 | Phase 2 | Apr 1, 2006 | GlaxoSmithKline |
| NCT00354666 | Phase 2 | Sep 1, 2004 | GlaxoSmithKline |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 2 | 2 | 1 | 2004 |
1 organizations
Page 1 / 1